It is increasingly appreciated that drug response to different cancers driven by the same oncogene is different and may relate to differences in rewiring of signal transduction. We aimed to study differences in dynamic signaling changes within mutant …
Background: KRAS mutant (KRAS MT) and RAS/BRAF wild type (RAS WT) colorectal
cancer (CRC) responds differently to targeted agents. A better understanding
of early effects on signal transduction following exposure to targeted agents
may explain this …
Background: Nearly two thirds of cancer patients will receive radiotherapy
(RT), with about 20% experiencing long-term RT-induced toxicity. Currently
patients cannot be stratified by risk of side effects, which restricts
treatment intensity for all …
Aims: To understand any context-dependent differences in signaling pathways
between pancreatic (PAN), colorectal (CR) and lung (LU) cancers with KRAS
mutations using a targeted phosphoproteomic approach in cell lines and
patient-derived cancer cells …